The Trump
administration has abruptly terminated a $258 million program dedicated
to developing HIV vaccines, causing widespread concern among scientists, health
experts, and policymakers. The program, led by Duke University and the
Scripps Research Institute, was making significant strides in HIV research
and also contributed to advancements in treatments for COVID-19, snake
antivenom, and autoimmune diseases.
Reasons for Cancellation
Officials from the National Institutes of Health (NIH) stated that the program was reviewed and deemed unnecessary, with the administration opting to shift focus to existing HIV treatments rather than vaccine development. Although antiretroviral therapies can effectively manage HIV, experts argue that they do not provide long-term immunity or a cure, making continued vaccine research vital.